ResApp Health Limited announced that the US Food and Drug Administration (FDA) has advised that, has not been approved and that additional information is required to demonstrate that the probable benefits of the device outweigh its probable risks. ResApp and the company's regulatory consultants, Experien Group, will now request an in-person meeting with the FDA review team to determine the company's next steps in the US, which may include a resubmission.